Skipping Hormone Therapy in Low-Risk Early Breast Cancer (NoELA)
No Endocrine Therapy in Small HR⁺/HER2- Low Risk Luminal A Early Breast Cancer, a Single-arm De-escalation Trial
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life.
All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy afterward. Participants will be enrolled for two years and followed for up to five years after the last participant is enrolled in the trial to monitor for long-term cancer recurrence.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Breast cancer is the most frequently diagnosed cancer among women worldwide. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors represent the predominant subtype and are generally associated with favorable outcomes. Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors, constitutes a cornerstone of treatment for HR+/HER2- early breast cancer and has demonstrated reductions in recurrence and mortality in large randomized trials and meta-analyses. However, these benefits were mainly established in populations including patients with a broader spectrum of recurrence risk.
The implementation of mammography screening programs has increased the detection of small, early-stage breast cancers, including tumors with excellent prognosis and very low risk of recurrence. In postmenopausal women with small node-negative Luminal A tumors, recurrence rates are particularly low, raising concerns regarding potential overtreatment and the balance between treatment benefit and toxicity.
Although ET is effective, its long-term administration is associated with substantial treatment burden and persistent toxicities, including musculoskeletal symptoms, vasomotor symptoms, fatigue, sexual dysfunction, mood disturbances, and bone loss. These adverse effects may significantly affect quality of life and contribute to treatment discontinuation. Observational data have suggested that ET-related quality-of-life impairment may persist longer than chemotherapy-related effects, particularly in postmenopausal women.
Retrospective studies have suggested that the absolute benefit of ET may be limited in selected patients with very low-risk disease, especially among older women with small, low-grade HR+/HER2- tumors. Furthermore, simulation models estimating individualized treatment benefit indicate that the absolute overall survival gain associated with ET in some low-risk subgroups may be minimal, with high numbers needed to treat.
Advances in biological characterization have enabled identification of Luminal A tumors, characterized by strong hormone receptor expression, low proliferative activity, and favorable prognosis. Combining biological characteristics with clinicopathological features such as age, tumor size, grade, and nodal status allows the identification of a subgroup of postmenopausal patients with exceptionally low risk of relapse.
NoELA was developed to prospectively evaluate a therapeutic de-escalation strategy consisting of omission of adjuvant ET in postmenopausal women presenting with very low-risk HR+/HER2- early breast cancer with Luminal A phenotype. The study focuses on patients expected to derive limited benefit from ET while remaining exposed to its long-term toxicity burden.
The study also aims to generate evidence supporting more individualized treatment strategies and improved shared decision-making by better quantifying the risk-benefit balance of ET omission in this population. In addition, comparison with external real-world data derived from patients treated with standard ET will help contextualize outcomes and improve the external validity of the findings.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Unicancer Project Leader
- Número de telefone: 0033 6 58 43 58 94
- E-mail: a-poitou@unicancer.fr
Locais de estudo
-
-
-
Angers, França
- Ainda não está recrutando
- ICO Angers
-
Contato:
- Dr PATSOURIS
-
Avignon, França
- Ainda não está recrutando
- Sainte Catherine, Institut du Cancer Avignon-Provence
-
Contato:
- Dr GRENIER
-
Bayeux, França
- Ainda não está recrutando
- Ch Aunay-Bayeux
-
Contato:
- Dr BRACHET
-
Bayonne, França
- Ainda não está recrutando
- CHCB
-
Contato:
- Dr GRELLETY
-
Bordeaux, França
- Ainda não está recrutando
- Institut Bergonie
-
Contato:
- Dr PETIT
-
Bordeaux, França
- Ainda não está recrutando
- Clinique Tivoli
-
Contato:
- Dr GARBAY
-
Boulogne-sur-Mer, França
- Ainda não está recrutando
- CH Boulogne sur Mer
-
Contato:
- Dr DESGROUSILLIERS
-
Brest, França
- Ainda não está recrutando
- Clinique Pasteur Lanroze
-
Contato:
- Dr LENGLET
-
Briis-sous-Forges, França
- Ainda não está recrutando
- CH de Bligny
-
Contato:
- Dr MERIC
-
Caen, França
- Ainda não está recrutando
- Centre François Baclesse
-
Contato:
- Dr EMILE
-
Chambray-lès-Tours, França
- Ainda não está recrutando
- Pole Sante Leonard de Vinci- Roc37
-
Contato:
- Dr BERNADOU
-
Clermont-Ferrand, França
- Ainda não está recrutando
- Centre Jean Perrin
-
Contato:
- Dr MOURET-REYNIER
-
Dechy, França
- Ainda não está recrutando
- Centre Leonard de Vinci
-
Contato:
- Dr ESCANDE
-
Dijon, França
- Ainda não está recrutando
- Centre Georges François Leclerc
-
Contato:
- Pr LADOIRE
-
La Roche-sur-Yon, França
- Ainda não está recrutando
- CHD Vendée
-
Contato:
- Dr LEGOUTE
-
Le Havre, França
- Ativo, não recrutando
- Centre Guillaume Le Conquérant
-
Lille, França
- Ativo, não recrutando
- Centre Oscar Lambret
-
Limoges, França
- Ainda não está recrutando
- CHU de Limoges
-
Contato:
- Pr DELUCHE
-
Lorient, França
- Recrutamento
- Groupe Hospitalier Bretagne Sud
-
Contato:
- Dr BERTHET
-
Lyon, França
- Ainda não está recrutando
- Hôpital privé Jean Mermoz
-
Contato:
- Dr DERBEL
-
Lyon, França
- Ativo, não recrutando
- Centre Léon Bérard
-
Marseille, França
- Ainda não está recrutando
- Institut Paoli-Calmettes
-
Contato:
- Pr GONCALVES
-
Marseille, França
- Ainda não está recrutando
- Hôpital Privé Clairval
-
Contato:
- Dr PAOLI
-
Mont-de-Marsan, França
- Ativo, não recrutando
- CHI de Mont-de-Marsan
-
Nice, França
- Ainda não está recrutando
- Centre Antoine Lacassagne
-
Contato:
- Dr GROULIER
-
Orléans, França
- Ainda não está recrutando
- Chu Orleans
-
Contato:
- Dr TOROSSIAN
-
Osny, França
- Ainda não está recrutando
- CHP Sainte Marie
-
Contato:
- Dr BLEICHNER
-
Paris, França
- Ainda não está recrutando
- Groupe hospitalier Paris saint Joseph
-
Contato:
- Dr SIMONAGGIO
-
Paris, França
- Ativo, não recrutando
- Institut Curie
-
Rennes, França
- Ainda não está recrutando
- Centre Eugene Marquis
-
Contato:
- Dr PERRIN
-
Rouen, França
- Ainda não está recrutando
- Centre Henri Becquerel
-
Contato:
- Dr VITUCCI
-
Saint-Cloud, França
- Ainda não está recrutando
- Institut Curie
-
Contato:
- Dr BELLO ROUFAI
-
Saint-Herblain, França
- Ainda não está recrutando
- Ico Saint Herblain
-
Contato:
- Dr FRENEL
-
Saint-Priest-en-Jarez, França
- Ainda não está recrutando
- CHU de Saint Etienne
-
Contato:
- Dr CORSINI
-
Strasbourg, França
- Ainda não está recrutando
- Centre de lutte contre le cancer - Paul Strauss
-
Contato:
- Dr BISCHOFF
-
Thonon-les-Bains, França
- Ainda não está recrutando
- Hopitaux du Leman
-
Contato:
- Dr CIOBANU
-
Toulouse, França
- Ainda não está recrutando
- IUCT-Oncopole
-
Contato:
- Pr DALENC
-
Tours, França
- Ainda não está recrutando
- CHU Tours
-
Contato:
- Dr LARRIVIERE
-
Vandœuvre-lès-Nancy, França
- Ainda não está recrutando
- Institut de Cancérologie de Lorraine
-
Contato:
- Dr CHARRA-BRUNAUD
-
Vantoux, França
- Ainda não está recrutando
- Groupe UNEOS-Hôpital Robert Schuman
-
Contato:
- Dr BENNA
-
Épagny, França
- Ativo, não recrutando
- CH Annecy Genevois
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Postmenopausal (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age.
- New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of nodal or distant metastatic disease.
- Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging.
- Negative axillary node involvement by sentinel node biopsy or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0) after mandatory ultrasound exploration without surgical exploration of the axilla if Breast Conservative Surgery (BCS) was performed.
- Estrogen Receptor (ER) positive (≥ 50%) and Progesterone Receptor(PR) positive (> 20%), Ki67 low (≤15%) and HER2 negative (IHC or In Situ Hybridization approach) according to ASCO (American Society of Clinical Oncology) criteria.
- Histological grade scored on the invasive component, 1 or 2 if pT1a or grade 1 if pT1b.
- Treated by mastectomy or BCS with microscopically clear resection margins defined as "no-ink on tumor" or ≥1 mm for invasive and non-invasive disease or no residual disease on re-excision.
- If BCS was performed, participants must have received or have scheduled adjuvant local radiotherapy (RT) within 3 months after surgery
- No indication of adjuvant chemotherapy.
- The participant is willing and able to comply with the protocol for the duration of the study, including scheduled visits, treatment strategy, laboratory tests and other study procedures.
- Participants must be affiliated with a Social Security System (or equivalent).
- The participant must have signed a written informed consent form before any trial-specific procedures. When the participant is physically unable to give written consent, an impartial witness of her choice, independent from the investigator or the sponsor, can confirm the participant's consent in writing.
Exclusion Criteria:
- Have received any neo-adjuvant treatment, including hormone therapy and chemotherapy.
- Have received or are eligible for adjuvant chemotherapy.
- Absolute contraindication for RT in case of BCS or patients who were treated with partial breast irradiation.
- Have been treated with mastectomy and with adjuvant radiotherapy received or scheduled.
- Invasive lobular breast cancer.
- Bilateral breast cancer or history of other invasive ipsi- or contralateral breast cancer.
- Multifocal or multicentric disease.
- Disease limited to microinvasion only (< 1 mm).
- Evidence of lymphovascular invasion.
- History of non-breast cancer malignancies if not disease-free for > 5 years and considered low risk of recurrence except for treated carcinoma in situ of the cervix, endometrium or colon, melanoma in situ and basal or squamous cell carcinoma of the skin.
- Non-malignant severe disease associated with a life expectancy < 10 years.
- Women with BRCA1, BRCA2 or other high-risk breast cancer predisposing deleterious germline mutations.
- Enrolled in another therapeutic study within 30 days prior to inclusion.
- Unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.
- Persons deprived of their liberty or under protective custody or guardianship.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: No Endocrine Therapy
The endocrine therapy will not be received by the participant during the study.
|
The standard of care endocrine therapy (Tamoxifene, Letrozole, Anastrozole or Exemestane) will not be received by the participant during the study.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Relapse-free interval
Prazo: At 5 years after the last treatment
|
Relapse-free interval (RFI) is defined as the delay between initial treatment and the first occurrence of i) ipsilateral breast tumor recurrence, ii) distant or locoregional recurrence or iii) death from breast cancer, according to the STEEP system definition version 2.0 (Tolaney SM et al., J Clin Oncol 2021)
|
At 5 years after the last treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Ipsilateral Ductal Carcinoma In Situ (DCIS)
Prazo: At 5 years after the last treatment
|
At 5 years after the last treatment
|
|
|
Incidence of invasive contralateral breast cancer
Prazo: At 5 years after the last treatment
|
At 5 years after the last treatment
|
|
|
Distant disease free survival (DDFS)
Prazo: At 5 years after the last treatment
|
Distant disease free survival is defined as the delay between date of inclusion and distant tumor relapse or death from any cause, whichever occurs first.
|
At 5 years after the last treatment
|
|
Relapse free survival (RFS)
Prazo: 5 years after the last treatment
|
Relapse-free survival is defined as the delay between date of inclusion and tumor relapse (local, regional, or distant) or death from any cause, whichever occurs first.
|
5 years after the last treatment
|
|
Overall survival (OS)
Prazo: At 5 years after the last treatment
|
The overall survival is the length of time from randomization that patients enrolled in the study are still alive.
|
At 5 years after the last treatment
|
|
Quality of life questionnaire - Core 30 (QLQ-C30)
Prazo: At baseline, 6 months, 1 year, and then annually until 5 years after the last inclusion
|
Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
At baseline, 6 months, 1 year, and then annually until 5 years after the last inclusion
|
|
Quality of Life Questionnaire - Breast cancer module (QLQ-BR42)
Prazo: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR42 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items. |
At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
|
Hospital anxiety and depression scale (HADS)
Prazo: At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale.
Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T).
Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale.
The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.
|
At baseline, 6 months, 1 year, and then annually until 5 year after the last inclusion
|
|
Bone-related events and osteopenia/osteoporosis diagnosis, dyslipidemia (hypercholesterolemia and hypertriglyceridemia) and cardiovascular events (myocardial infarction, stroke, and thromboembolic events), as per CTCAE v6.0
Prazo: Throughout study completion, up to 5 years after the last inclusion
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 6 (NCI-CTCAE v6) is widely accepted in the community of oncology research as the leading rating scale for adverse events.
This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.
|
Throughout study completion, up to 5 years after the last inclusion
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jean-Yves PIERGA, MD, Institut Curie
- Investigador principal: José Luis SANDOVAL, MD, University Hospital, Geneva
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UC-BCG-2513
- 2025-523683-20-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .